NCT03220373

Brief Summary

The aim of this project is to gain a more specific understanding of how different cognitive profiles predict residential treatment drop-out, treatment retention and post-treatment outcome in a population with Substance Use Disorder.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
43mo left

Started Mar 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Mar 2017Dec 2029

Study Start

First participant enrolled

March 7, 2017

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

March 8, 2017

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 18, 2017

Completed
12.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

January 5, 2024

Status Verified

January 1, 2024

Enrollment Period

12.8 years

First QC Date

March 8, 2017

Last Update Submit

January 3, 2024

Conditions

Substance Use Disorder (SUD)

Keywords

NeuropsychologyCognitionDrop-outFollow-up

Outcome Measures

Primary Outcomes (2)

  • Exit reason

    Reason for terminating residential SUD treatment (Treatment completed or Drop-out)

    On average 3 months

  • Treatment retention

    Number of days in treatment

    On average 3 months

Secondary Outcomes (6)

  • Substance use

    1 year after neuropsychological assessment

  • Psychological distress

    1 year after neuropsychological assessment

  • Quality of Life

    1 year after neuropsychological assessment

  • ADHD symptoms

    1 year after neuropsychological assessment

  • Income

    1 year after neuropsychological assessment

  • +1 more secondary outcomes

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Treatment seeking Substance Use Disorder (SUD) patients.

You may qualify if:

  • Substance Use Disorder (SUD) patients.
  • years or older.
  • Qualified to consent to research participation.
  • Able to speak and write in Norwegian.

You may not qualify if:

  • Not qualified to consent to research participation.
  • Insufficient understanding of Norwegian.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oslo University Hospital

Oslo, 0320, Norway

Location

MeSH Terms

Conditions

Substance-Related Disorders

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersMental Disorders

Study Officials

  • Espen Walderhaug, PhD

    Oslo University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 8, 2017

First Posted

July 18, 2017

Study Start

March 7, 2017

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

January 5, 2024

Record last verified: 2024-01

Locations

NO(1)